Bryzant Labs has been accepted into NVIDIA's Inception program and Innovation Lab, providing access to high-performance computing resources for protein structure prediction and molecular simulation in support of the SMA computational discovery platform.

The recognition supports the platform's multi-method, AI-orchestrated approach to early-stage hypothesis generation in spinal muscular atrophy. It does not constitute clinical or therapeutic validation; the platform's outputs remain computational predictions pending experimental testing.